Press releases

12 Jun 2025

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

12 Jun 2025

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

11 Jun 2025

BIMZELX[®]▼(bimekizumab) three-year data at EULAR 2025 showed lasting efficacy and control of inflammation in psoriatic arthritis and axial spondyloarthritis

19 May 2025

UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences

13 May 2025

UCB presents expansive data set at 15th Myasthenia Gravis Foundation of America (MGFA) International Conference highlighting commitment to advancing gMG treatment outcomes and experiences

9 May 2025

RYSTIGGO[®] (rozanolixizumab) receives approval in Japan for two new administration methods as UCB begins ONWARD program for patient support

Press releases

Press releases

Search Press releases

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

BIMZELX[®]▼(bimekizumab) three-year data at EULAR 2025 showed lasting efficacy and control of inflammation in psoriatic arthritis and axial spondyloarthritis

UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences

UCB presents expansive data set at 15th Myasthenia Gravis Foundation of America (MGFA) International Conference highlighting commitment to advancing gMG treatment outcomes and experiences

RYSTIGGO[®] (rozanolixizumab) receives approval in Japan for two new administration methods as UCB begins ONWARD program for patient support

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

Global data show real-world effectiveness of romosozumab for patients at high fracture risk

BIMZELX[®] (bimekizumab-bkzx) five-year data at AAD 2025 showed sustained skin clearance and long...

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

UCB completes sale of established brands and updates 2024 financial guidance

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

BIMZELX[®]▼(bimekizumab) three-year data at EULAR 2025 showed lasting efficacy and control of inflammation in psoriatic arthritis and axial spondyloarthritis

UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences

UCB presents expansive data set at 15th Myasthenia Gravis Foundation of America (MGFA) International Conference highlighting commitment to advancing gMG treatment outcomes and experiences

RYSTIGGO[®] (rozanolixizumab) receives approval in Japan for two new administration methods as UCB begins ONWARD program for patient support

Choose a Country